Register Login

CONNECT BIOPHARMA HOLDINGS LTD (CNTB)

(90% Positive) CONNECT BIOPHARMA HOLDINGS LTD (CNTB) Announces Enrollment Update for improvement Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 12, 2026, 8:28 p.m.

    📋 CONNECT BIOPHARMA HOLDINGS LTD (CNTB) - Clinical Trial Update

    Filing Date: 2026-08-12

    Accepted: 2026-08-12 16:13:33

    Event Type: Clinical Trial Update

    Event Details:

    CONNECT BIOPHARMA HOLDINGS LTD (CNTB) Announces Clinical Trial Update CONNECT BIOPHARMA HOLDINGS LTD (CNTB) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: improvement, track
    • Diseases/Conditions: lung function
    • Clinical Stage: Phase 2
    • Collaboration: Company
      • expected in September 2026
      • targeting interleukin-4 receptor alpha (IL-4Rα), a common subunit of interleukin-4 receptor (IL-4) and interleukin-13 receptor (IL-13). We believe that by binding with IL-4Rα, rademikibart can block the functions of IL-4 and IL-13 effectively, thereby blocking the T helper 2 (Th2) inflammatory pathway to achieving the goal of treating Th2 related inflammatory diseases such as atopic dermatitis, asthma and COPD. About Connect Biopharma Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $99 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China. For more information visit www.connectbiopharma.com. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CONNECT BIOPHARMA HOLDINGS LTD
    • Ticker Symbol: CNTB

Search

News categories